Key Insights

Highlights

Success Rate

83% trial completion

Published Results

172 trials with published results (21%)

Research Maturity

401 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

10.5%

84 terminated out of 803 trials

Success Rate

82.7%

-3.8% vs benchmark

Late-Stage Pipeline

11%

89 trials in Phase 3/4

Results Transparency

43%

172 of 401 completed with results

Key Signals

172 with results83% success84 terminated

Data Visualizations

Phase Distribution

585Total
Not Applicable (201)
Early P 1 (14)
P 1 (133)
P 2 (148)
P 3 (65)
P 4 (24)

Trial Status

Completed401
Recruiting133
Terminated84
Unknown62
Active Not Recruiting54
Withdrawn30

Trial Success Rate

82.7%

Benchmark: 86.5%

Based on 401 completed trials

Clinical Trials (803)

Showing 20 of 20 trials
NCT05012631Phase 2CompletedPrimary

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

NCT04349189CompletedPrimary

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

NCT07599176Phase 1RecruitingPrimary

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

NCT05730205Phase 4Active Not RecruitingPrimary

Effects of the Contraceptive Implant in Women With Sickle Cell Disease

NCT03958643CompletedPrimary

Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy

NCT07640815UnknownPrimary

Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease

NCT06609226Phase 3RecruitingPrimary

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT04417673Completed

Living With Sickle Cell Disease in the COVID-19 Pandemic

NCT05407805CompletedPrimary

A Study to Learn About Sickle Cell Disease In Adult Patients

NCT02720679Recruiting

Investigation of the Genetics of Hematologic Diseases

NCT00011648Completed

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

NCT04657822Phase 4RecruitingPrimary

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

NCT00542230Recruiting

Blood Sampling for Research Related to Sickle Cell Disease

NCT00047996Enrolling By InvitationPrimary

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

NCT03937817Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

NCT07252050Phase 1RecruitingPrimary

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

NCT07392216RecruitingPrimary

Functional Ovarian Reserve in Sickle Cell Disease

NCT06689800Not ApplicableRecruiting

Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

NCT06872333Phase 2Recruiting

Allo HSCT for High Risk Hemoglobinopathies

NCT02098863RecruitingPrimary

Sickle Cell Clinical Research and Intervention Program

Scroll to load more

Research Network

Activity Timeline